Esperion Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $82,385 | $64,995 | $69,113 | $51,632 |
Gross Profit | 61,776 | 33,457 | 43,482 | 34,346 |
EBITDA | 15,695 | -20,998 | -4,869 | -14,416 |
EBIT | 15,721 | -21,024 | -4,896 | -14,442 |
Net Income | -4,791 | -40,455 | -21,318 | -29,524 |
Net Change In Cash | 82,385 | 64,995 | 69,113 | 51,632 |
Free Cash Flow | -31,422 | -22,628 | -34,952 | -35,492 |
Cash | 86,061 | 114,633 | 144,761 | 144,717 |
Basic Shares | 196,841 | 196,127 | 195,566 | 194,930 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $332,314 | $116,334 | $75,475 | $78,447 |
Gross Profit | 263,713 | 73,067 | 48,508 | 64,230 |
EBITDA | 7,569 | -150,108 | -176,349 | -222,143 |
EBIT | 7,506 | -150,272 | -176,849 | -222,755 |
Net Income | -51,745 | -209,248 | -287,817 | -318,824 |
Net Change In Cash | 332,314 | 116,334 | 75,475 | 78,447 |
Cost of Revenue | -134,117 | -46,070 | ||
Free Cash Flow | -23,971 | -135,487 | -174,827 | -263,809 |
Cash | 144,761 | 82,248 | 124,775 | 208,892 |
Basic Shares | 187,181 | 103,106 | 66,407 | 28,902 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | -$0.02 |
2025-03-31 | -$0.20 |
2024-12-31 | -$0.10 |
